OBJECTIVE： To evaluate the effects of loading-dose rosuvastatin on vascular endothelial function in patients with non-ST segment elevation acute coronary syndromes （NSTE-ACS） after early interventional therapy. METHODS： Totally of 128 NSTE-ACS patients underwent early interventional therapy were randomly divided into conventional dose group （63 cases） and loading dose group （65 cases）. Before operation， all patients were given Clopidogrel sulfate tablets 300 mg and Aspirin enteric-coated tablets 100 mg； on this basis， conventional dose group was given Rosuvastatin calcium tablets 10 mg orally； loading dose group was given Rosuvastatin calcium tablets 20 mg orally. After PCI， both groups were given Rosuvastatin calcium tablets 10 mg orally， qd， and Aspirin enteric-coated tablets （100 mg/d） and Clopidogrel sulfate tablets （75 mg/d）， for consecutive 3 months. The blood samples were collected before surgery， 8 h and 24 h after surgery. The serum levels of CK-MB， cTn T， hs-CRP， ET and NO were detected. The occurrence of major adverse cardiovascular events was recorded within 3 months after surgery.  RESULTS： Compared with before surgery， the serum levels of CK-MB， cTn T， hs-CRP and ET were increased significantly 8 h and 24 h after surgery， while the level of NO was decreased， with statistical significance （P＜0.05）. However， the change range of loading dose group was lesser than that of conventional dose group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of adverse cardiovascular events between 2 groups （P＞0.05）. CONCLUSIONS： For NSTE-ACS patients underwent early interventional therapy， loading dose of rosuvastatin can protect the patients and inhibit the injury of vascular endothelial cell induced by the surgery.